• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Cellectis S.A. - American Depositary Shares (NQ:CLLS)

    3.630 +0.130 (+3.71%)
    Streaming Delayed Price Updated: 9:50 AM EDT, Mar 17, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 6,877
    Open 3.640
    Bid (Size) 3.610 (1,000)
    Ask (Size) 3.680 (100)
    Prev. Close 3.500
    Today's Range 3.610 - 3.725
    52wk Range 1.100 - 5.480
    Shares Outstanding 45,484,310
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Cellectis to Report Fourth Quarter and Full Year 2025 Financial Results on March 19, 2026
    From Cellectis Inc.
    Via GlobeNewswire
    News headline image
    Cellectis Announces 2026 Strategy and Catalysts
    From Cellectis Inc.
    Via GlobeNewswire

    Performance

    YTD
    -24.4%
    -24.4%
    1 Month
    -6.4%
    -6.4%
    3 Month
    -24.2%
    -24.2%
    6 Month
    +21.4%
    +21.4%
    1 Year
    +196.3%
    +196.3%

    More News

    Read More
    News headline image
    Traders are paying attention to the gapping stocks in Monday's session. ↗
    Via Chartmill
    News headline image
    Cellectis Earnings Preview ↗
    Via Benzinga
    News headline image
    Allogene Therapeutics Reports Favorable Result for Servier in Arbitration with Cellectis
    From Allogene Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Cellectis Announces Arbitral Decision in Dispute with Servier
    From Cellectis Inc.
    Via GlobeNewswire
    News headline image
    ASH 2025: Cellectis Presents Development Plan to Further Enhance High Response Rate Observed for Eti-cel in r/r NHL
    From Cellectis Inc.
    Via GlobeNewswire
    News headline image
    Why Cellectis Stock Is Trading Higher Today ↗
    Via Benzinga
    News headline image
    European ADRs Navigate Choppy Waters: Pharma Sector Shows Resilience Amidst Broader Market Volatility
    Via MarketMinute
    Topics Artificial Intelligence Economy Supply Chain
    News headline image
    Cellectis Publishes Nature Communications Article on a Non-Viral Gene Editing Process Enabling Efficient Gene Insertion in Hematopoietic Stem Cells
    From Cellectis Inc.
    Via GlobeNewswire
    News headline image
    Cellectis Reports Third Quarter 2025 Financial Results and Provides Business Update
    From Cellectis Inc.
    Via GlobeNewswire
    News headline image
    Earnings Scheduled For November 7, 2025 ↗
    Via Benzinga
    News headline image
    Cellectis to Present a Development Update for eti-cel at ASH 2025
    From Cellectis Inc.
    Via GlobeNewswire
    News headline image
    Cellectis to Report Third Quarter Financial Results on November 7, 2025
    From Cellectis Inc.
    Via GlobeNewswire
    News headline image
    Olema Pharmaceuticals, Exelixis, Genmab And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗
    Via Benzinga
    News headline image
    Cellectis’ R&D Day Highlights Lasme-cel’s Potential to Address Significant Unmet Need for Patients with r/r B-ALL
    From Cellectis Inc.
    Via GlobeNewswire
    News headline image
    Thursday's session: gap up and gap down stocks ↗
    Via Chartmill
    News headline image
    Enerpac Tool Group Posts Upbeat Results, Joins Praxis Precision Medicines, J B Hunt, Salesforce And Other Big Stocks Moving Higher On Thursday ↗
    Via Benzinga
    News headline image
    Top 2 Health Care Stocks That May Keep You Up At Night This Month ↗
    Via Benzinga
    News headline image
    Stay updated with the stocks that are on the move in today's pre-market session. ↗
    Via Chartmill
    News headline image
    Cellectis Hosts R&D Day Today Showcasing Pipeline Progress and Long-Term Value Drivers
    From Cellectis Inc.
    Via GlobeNewswire
    News headline image
    Cellectis to Present Data on Non-Viral Gene Therapy and TALE Base Editors at the ESGCT Annual Congress
    From Cellectis Inc.
    Via GlobeNewswire
    News headline image
    Wondering what's happening in today's pre-market session? ↗
    Via Chartmill
    News headline image
    12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
    Via Benzinga
    News headline image
    Inventiva, MoonLake Immunotherapeutics And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗
    Via Benzinga
    Topics Stocks

    Frequently Asked Questions

    Is Cellectis S.A. - American Depositary Shares publicly traded?
    Yes, Cellectis S.A. - American Depositary Shares is publicly traded.
    What exchange does Cellectis S.A. - American Depositary Shares trade on?
    Cellectis S.A. - American Depositary Shares trades on the Nasdaq Stock Market
    What is the ticker symbol for Cellectis S.A. - American Depositary Shares?
    The ticker symbol for Cellectis S.A. - American Depositary Shares is CLLS on the Nasdaq Stock Market
    What is the current price of Cellectis S.A. - American Depositary Shares?
    The current price of Cellectis S.A. - American Depositary Shares is 3.630
    When was Cellectis S.A. - American Depositary Shares last traded?
    The last trade of Cellectis S.A. - American Depositary Shares was at 03/17/26 09:50 AM ET
    What is the market capitalization of Cellectis S.A. - American Depositary Shares?
    The market capitalization of Cellectis S.A. - American Depositary Shares is 165.11M
    How many shares of Cellectis S.A. - American Depositary Shares are outstanding?
    Cellectis S.A. - American Depositary Shares has 165M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.